Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H35NO2.ClH |
| Molecular Weight | 345.948 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2
InChI
InChIKey=GUBNMFJOJGDCEL-UHFFFAOYSA-N
InChI=1S/C19H35NO2.ClH/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17;/h17H,3-16H2,1-2H3;1H
| Molecular Formula | C19H35NO2 |
| Molecular Weight | 309.4867 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Dicyclomine is an anticholinergic tertiary amine used frequently by oral and parenteral route as an effective anti-spasmodic agent. Dicyclomine hydrochloride salt is approved under brand name bentyl for the treatment of functional bowel/irritable bowel syndrome. In addition is known, that dicyclomine is also used in morning and motion sickness, dysmenorrheal, intestinal hypermotility. It was shown, that Dicyclomine is a selective M1 and M3 muscarinic receptors antagonist, but os shown pharmacological activity via the M1 receptor.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2432979 |
|||
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3612532 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | BENTYL Approved UseDicyclomine hydrochloride oral solution is indicated for the treatment of functional bowel/irritable bowel syndrome. Launch Date1984 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
47.98 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DICYCLOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
50.47 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DICYCLOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
207.88 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DICYCLOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
202.67 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DICYCLOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.09 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DICYCLOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.66 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DICYCLOMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.8 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DICYCLOMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
600 mg single, oral Highest recorded dose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: |
unhealthy, 10 months Health Status: unhealthy Age Group: 10 months Sex: unknown Sources: |
|
1500 mg single, oral Highest recorded dose Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
|
40 mg 4 times / day multiple, oral Recommended Dose: 40 mg, 4 times / day Route: oral Route: multiple Dose: 40 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Other AEs: Dry mouth, Dizziness... Other AEs: Dry mouth (33%) Sources: Dizziness (40%) Vision blurred (27%) Nausea (14%) Somnolence (9%) Asthenia (7%) Nervousness (6%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Nausea | 14% | 40 mg 4 times / day multiple, oral Recommended Dose: 40 mg, 4 times / day Route: oral Route: multiple Dose: 40 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
| Vision blurred | 27% | 40 mg 4 times / day multiple, oral Recommended Dose: 40 mg, 4 times / day Route: oral Route: multiple Dose: 40 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
| Dry mouth | 33% | 40 mg 4 times / day multiple, oral Recommended Dose: 40 mg, 4 times / day Route: oral Route: multiple Dose: 40 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
| Dizziness | 40% | 40 mg 4 times / day multiple, oral Recommended Dose: 40 mg, 4 times / day Route: oral Route: multiple Dose: 40 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
| Nervousness | 6% | 40 mg 4 times / day multiple, oral Recommended Dose: 40 mg, 4 times / day Route: oral Route: multiple Dose: 40 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
| Asthenia | 7% | 40 mg 4 times / day multiple, oral Recommended Dose: 40 mg, 4 times / day Route: oral Route: multiple Dose: 40 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
| Somnolence | 9% | 40 mg 4 times / day multiple, oral Recommended Dose: 40 mg, 4 times / day Route: oral Route: multiple Dose: 40 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. | 2013-02 |
|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011-07-14 |
|
| A computer-automated touchscreen paired-associates learning (PAL) task for mice: impairments following administration of scopolamine or dicyclomine and improvements following donepezil. | 2011-03 |
|
| Opioid substitution therapy in manipur and nagaland, north-east india: operational research in action. | 2010-12-01 |
|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010-12 |
|
| Survey on the use of psychotropic drugs by twelve military police units in the municipalities of Goiânia and Aparecida de Goiânia, state of Goiás, Brazil. | 2010-12 |
|
| Acupuncture reduces crying in infants with infantile colic: a randomised, controlled, blind clinical study. | 2010-12 |
|
| New approaches in the management of multiple sclerosis. | 2010-11-24 |
|
| Rhabdomyolysis associated with phentermine. | 2010-11-15 |
|
| Chiropractic diagnosis and management of non-musculoskeletal conditions in children and adolescents. | 2010-06-02 |
|
| Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions. | 2010-04-07 |
|
| Use of potentially inappropriate medicines in elderly: A prospective study in medicine out-patient department of a tertiary care teaching hospital. | 2010-04 |
|
| Antispasmodic and bronchodilator activities of Artemisia vulgaris are mediated through dual blockade of muscarinic receptors and calcium influx. | 2009-12-10 |
|
| Fustin flavonoid attenuates beta-amyloid (1-42)-induced learning impairment. | 2009-12 |
|
| Oxybutynin extended release for the management of overactive bladder: a clinical review. | 2009-09-21 |
|
| Rapid Hemodynamic Deterioration and Death due to Acute Severe Refractory Septic Shock. | 2009-06 |
|
| Development of functional gastrointestinal disorders after Giardia lamblia infection. | 2009-04-21 |
|
| [Characterization of muscarinic receptors in undifferentiated thyroid cells in Fisher rats]. | 2009-03 |
|
| Self-medication for infants with colic in Lagos, Nigeria. | 2009-02-04 |
|
| Liver Injury with Features Mimicking Autoimmune Hepatitis following the Use of Black Cohosh. | 2009 |
|
| Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. | 2008-11-13 |
|
| Dicyclomine, an M1 muscarinic antagonist, reduces biomarker levels, but not neuronal degeneration, in fluid percussion brain injury. | 2008-11 |
|
| Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. | 2008-11 |
|
| Interaction between glutamatergic-NMDA and cholinergic-muscarinic systems in classical fear conditioning. | 2008-09-30 |
|
| Antagonism of muscarinic M1 receptors by dicyclomine inhibits the consolidation of morphine-associated contextual memory. | 2008-07-01 |
|
| Anticholinergic activity of 107 medications commonly used by older adults. | 2008-07 |
|
| Blockade of M1 muscarinic acetylcholine receptors modulates the methamphetamine-induced psychomotor stimulant effect. | 2008-06-02 |
|
| Topiramate induced acute angle closure glaucoma. | 2008-03-28 |
|
| Mechanisms underlying the antispasmodic and bronchodilatory properties of Terminalia bellerica fruit. | 2008-03-28 |
|
| Gastrointestinal, selective airways and urinary bladder relaxant effects of Hyoscyamus niger are mediated through dual blockade of muscarinic receptors and Ca2+ channels. | 2008-02 |
|
| Idiopathic (primary) achalasia. | 2007-09-26 |
|
| Improving the detection limits of antispasmodic drugs electrodes by using modified membrane sensors with inner solid contact. | 2007-05-09 |
|
| [Drug treatment of irritable bowel syndrome: an unmet need]. | 2007-03 |
|
| American Gastroenterological Association institute medical position statement on the use of gastrointestinal medication in pregnancy. | 2007-02 |
|
| Role of muscarinic M1 receptors in inhibitory avoidance and contextual fear conditioning. | 2006-09 |
|
| Current gut-directed therapies for irritable bowel syndrome. | 2006-07 |
|
| Clinical inquiries. What is the best treatment for infants with colic? | 2006-07 |
|
| M1 receptors play a central role in modulating AD-like pathology in transgenic mice. | 2006-03-02 |
|
| Treatment of overactive bladder in the aging population: focus on darifenacin. | 2006 |
|
| The negative impact of litigation on women's health care. | 2005-12 |
|
| Interaction between M1-muscarinic and glutamatergic NMDA receptors on an inhibitory avoidance task. | 2005-11-30 |
|
| Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. | 2005-11 |
|
| Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies. | 2005-06-20 |
|
| Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. | 2005-06 |
|
| Infantile colic. | 2005-06 |
|
| Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9. | 1998-03 |
|
| Aplastic anaemia associated with piroxicam. | 1991-02 |
|
| The effect of M1 muscarinic blockade on behavior and physiological responses following traumatic brain injury in the rat. | 1990-03-12 |
|
| Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. | 1989-04 |
|
| Dicyclomine: worrying symptoms associated with its use in some small babies. | 1984-03-24 |
Patents
Sample Use Guides
Adults-Oral. The only oral dose clearly shown to be effective is 160 mg per day (in 4 equally divided doses). Since this dose is associated with a significant incidence of side effects, it is prudent to begin with 80 mg per day (in 4 equally divided doses). Depending upon the patient’s response during the first week of therapy, the dose should be increased to 160 mg per day unless side effects limit dosage escalation. If efficacy is not achieved within 2 weeks or side effects require doses below 80 mg per day, the drug should be discontinued. Documented safety data are not available for doses above 80 mg daily for periods longer than 2 weeks.
Adults-Intramuscular Injection. NOT FOR INTRAVENOUS USE. The intramuscular dosage form is to be used temporarily when the patient cannot take oral medication. Intramuscular injection is about twice as bioavailable as oral dosage forms; consequently, the recommended intramuscular dose is 80 mg daily (in 4 equally divided doses). Oral dicyclomine hydrochloride should be started as soon as possible and the intramuscular form should not be used for periods longer than 1 or 2 days.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14723484
Dicyclomine showed inhibitory action against several pathogenic bacteria. Dicyclomine inhibited most of the bacterial isolates tested at 25-100 microg/ml concentration, and a few were sensitive even at a lower concentration (10 microg/ml). Dicyclomine was found to be bacteriostatic in nature against Shigella dysenteriae 7, and bactericidal against S. aureus NCTC 6571, 8530, and 8531.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:48:36 GMT 2025
by
admin
on
Mon Mar 31 17:48:36 GMT 2025
|
| Record UNII |
CQ903KQA31
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 310.201
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
||
|
NCI_THESAURUS |
C29704
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
||
|
NCI_THESAURUS |
C29698
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C28987
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | |||
|
441344
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | |||
|
100000090526
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | |||
|
CQ903KQA31
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | |||
|
SUB01676MIG
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | |||
|
67-92-5
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | |||
|
1191000
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | |||
|
152021
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID0058778
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | |||
|
m4378
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL1123
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | |||
|
200-671-1
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | |||
|
DBSALT000698
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | |||
|
4515
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | |||
|
404381
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY | |||
|
CQ903KQA31
Created by
admin on Mon Mar 31 17:48:36 GMT 2025 , Edited by admin on Mon Mar 31 17:48:36 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |